107 related articles for article (PubMed ID: 26146158)
1. Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression.
Zhu J; Liu R; Jiang Z; Wang P; Yao Y; Shen Z
J Biomed Inform; 2015 Oct; 57():20-7. PubMed ID: 26146158
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic models for myelosuppression.
Friberg LE; Karlsson MO
Invest New Drugs; 2003 May; 21(2):183-94. PubMed ID: 12889739
[TBL] [Abstract][Full Text] [Related]
4. Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide/carboplatin/etoposide) regimen for malignant gliomas.
Yano Y; Kodawara T; Hongo H; Yano I; Kishi Y; Takahashi J; Inui K
J Pharm Sci; 2009 Nov; 98(11):4402-12. PubMed ID: 19593785
[TBL] [Abstract][Full Text] [Related]
5. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
Barbolosi D; Freyer G; Ciccolini J; Iliadis A
Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
7. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment in oncology clinical practice. From risk factors to risk models.
Lyman GH
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
[TBL] [Abstract][Full Text] [Related]
9. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
11. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
Iliadis A; Barbolosi D
Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
[TBL] [Abstract][Full Text] [Related]
12. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
Netterberg I; Nielsen EI; Friberg LE; Karlsson MO
Cancer Chemother Pharmacol; 2017 Aug; 80(2):343-353. PubMed ID: 28656382
[TBL] [Abstract][Full Text] [Related]
13. Myelosuppression and its consequences in elderly patients with cancer.
Balducci L
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):27-32. PubMed ID: 14682116
[TBL] [Abstract][Full Text] [Related]
14. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
[TBL] [Abstract][Full Text] [Related]
16. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
17. A tool for neutrophil guided dose adaptation in chemotherapy.
Wallin JE; Friberg LE; Karlsson MO
Comput Methods Programs Biomed; 2009 Mar; 93(3):283-91. PubMed ID: 19084287
[TBL] [Abstract][Full Text] [Related]
18. Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. Gruppo Italiano Studio Carcinomi Apparato Digerente.
Zaniboni A; Labianca R; Pancera G; Barni S; Frontini L; Marini G; Luporini G
J Chemother; 1995 Jun; 7(3):246-8. PubMed ID: 7562022
[TBL] [Abstract][Full Text] [Related]
19. The role of myelopoietic growth factors in managing cancer in the elderly.
Balducci L; Carreca I
Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
[TBL] [Abstract][Full Text] [Related]
20. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Soto E; Keizer RJ; Trocóniz IF; Huitema AD; Beijnen JH; Schellens JH; Wanders J; Cendrós JM; Obach R; Peraire C; Friberg LE; Karlsson MO
Invest New Drugs; 2011 Oct; 29(5):984-95. PubMed ID: 20449627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
